曲妥珠单抗进展后治疗：对转化肿瘤学的挑战？ - Suppr

Suppr

超能文献

Trastuzumab beyond progression: a challenge to translational oncology?

作者信息

Santoro A, Gullo G

机构信息

Oncology and Haematology Unit, Istituto Clinico Humanitas, Rozzano, Milan, Italy.

Department of Oncology, St Vincent's University Hospital, Dublin, Ireland.

出版信息

Ann Oncol. 2010 Nov;21(11):2131-2134. doi: 10.1093/annonc/mdq410. Epub 2010 Aug 23.

DOI:10.1093/annonc/mdq410

PMID:20732933

Abstract

摘要

相似文献

Trastuzumab beyond progression: a challenge to translational oncology?曲妥珠单抗进展后治疗：对转化肿瘤学的挑战？

Ann Oncol. 2010 Nov;21(11):2131-2134. doi: 10.1093/annonc/mdq410. Epub 2010 Aug 23.

[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].[肿瘤学中靶向治疗的应用及其对临床试验设计的影响：以表皮生长因子受体1和2为例]

Med Clin (Barc). 2013 Aug 17;141(4):176-80. doi: 10.1016/j.medcli.2013.04.008. Epub 2013 Jun 27.

Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.在接受新辅助化疗和曲妥珠单抗治疗的HER2阳性乳腺癌中加入抗糖尿病药物二甲双胍：加泰罗尼亚肿瘤研究所正在进行的临床转化研究经验。

Ann Oncol. 2010 Jan;21(1):187-9. doi: 10.1093/annonc/mdp494. Epub 2009 Nov 2.

Trastuzumab.曲妥珠单抗

Cancer Treat Res. 2009;151:181-96. doi: 10.1007/978-0-387-75115-3_12.

New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.使用赫赛汀（曲妥珠单抗）进行的新型分子靶向治疗，赫赛汀是一种抗HER2（c-erB-2）单克隆抗体。

Breast Cancer. 2000;7(4):350-7. doi: 10.1007/BF02966404.

Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.HER-2阳性转移性乳腺癌脑转移进展后继续使用曲妥珠单抗的临床效用

Oncologist. 2007 Dec;12(12):1467-9; author reply 1469-71. doi: 10.1634/theoncologist.12-12-1467.

Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914).

Ann Oncol. 2006 May;17(5):875; reply 875-6. doi: 10.1093/annonc/mdj074. Epub 2005 Nov 22.

Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.曲妥珠单抗及其他：HER2阳性乳腺癌治疗的新可能性

Oncology (Williston Park). 2006 Dec;20(14):1763-71; discussion 1771-2, 1774-6.

Trastuzumab-treated advanced breast cancer patients and brain metastases: just a little alert.

Ann Oncol. 2008 Jan;19(1):191. doi: 10.1093/annonc/mdm530.

The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.表皮生长因子受体1和表皮生长因子受体2通路抑制在乳腺癌治疗中的未来：靶向多种受体

Oncologist. 2004;9 Suppl 3:1-3. doi: 10.1634/theoncologist.9-suppl_3-1.

引用本文的文献

Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016).澳大利亚人 HER2 阳性转移性乳腺癌处方限制的遵守情况：一项全国性基于人群的观察性研究（2001-2016 年）。

PLoS One. 2018 Jul 26;13(7):e0198152. doi: 10.1371/journal.pone.0198152. eCollection 2018.

Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?一种用于筛选和评估转移性疾病中抗癌药物成本与生存获益的新方法：成本是否应该纳入评估？

J Oncol Pract. 2012 Jul;8(4):224-30. doi: 10.1200/JOP.2011.000390.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验